hotspot -WSS

hotspot

author：hotspot 2025-10-01 01:00:23 - browse：74573

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： 'Make People Better': The CRISPR babies story you probably don't know

WSS

Listen: More tumult at BIO & coercive care for sickle cell patients

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Making the case for fair compensation in clinical trials

ALS advocates say criticism of new drugs misses bigger picture

AstraZeneca chief proposes a novel edit to the drug pricing bill

Bird flu surveillance in wastewater gets boost from consortium

knowledge

hotspot

focus

After affirmative action ruling, medical educators look to 'holistic review'

Liver decline slowed by off

Walensky prepares to leave CDC — and Congress — behind

H5N1 virus can be tracked in retail milk, scientists say

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Trump surgeon general acknowledges mistakes during Covid

After affirmative action ruling, medical educators look to 'holistic review'

ALS advocates say criticism of new drugs misses bigger picture

New air purifier tech could be key to improving indoor air quality

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Wikipedia

How generative AI is inspiring dreams of a health data revolution

How to fix cancer clinical trials' diversity problem

How generative AI is inspiring dreams of a health data revolution

Trump surgeon general acknowledges mistakes during Covid

UnitedHealth argues against case alleging wrongful AI care denials

Listen: Biogen's potential pivot, & Illumina's next chapter

hotspot

leisure time

hotspot

hotspot